TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to study the effect of anticoagulation in immune response with Acute Kidney Injury (AKI) undergoing Continuous Renal Replacement Therapy (CRRT).


Options:
A: Arm Label: AKI requring CRRT and use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with regional citrate anticoagulation | Arm Label: AKI requring CRRT and not use regional citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Procedure: Continuous renal replacement therapy with no anticoagulation or heparin | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with regional citrate anticoagulation; Assigned to Arm(s): AKI requring CRRT and use regional citrate anticoagulation | Intervention Type: PROCEDURE; Name: Continuous renal replacement therapy with no anticoagulation or heparin; Assigned to Arm(s): AKI requring CRRT and not use regional citrate anticoagulation
B: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation
C: Arm Label: heparin; Type: ACTIVE_COMPARATOR; Interventions: Other: regional anticoagulation with citrate | Arm Label: Citrate; Type: ACTIVE_COMPARATOR; Interventions: Other: HfCitPre | Intervention Type: OTHER; Name: regional anticoagulation with citrate; Assigned to Arm(s): heparin | Intervention Type: OTHER; Name: HfCitPre; Assigned to Arm(s): Citrate
D: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The aim of this study was to investigate and compared the effects of cervical and scapulothoracic stabilization exercises with and without connective tissue massage (CTM) for patients with chronic mechanical neck pain.


Options:
A: Arm Label: High dose spinal manipulation; Type: EXPERIMENTAL; Interventions: Other: Spinal Manipulation | Arm Label: Moderate dose spinal manipulation; Type: EXPERIMENTAL; Interventions: Other: Spinal Manipulation, Other: Light Massage | Arm Label: Low dose spinal manipulation; Type: EXPERIMENTAL; Interventions: Other: Spinal Manipulation, Other: Light Massage | Arm Label: High dose massage; Type: OTHER; Interventions: Other: Light Massage | Intervention Type: OTHER; Name: Spinal Manipulation; Assigned to Arm(s): High dose spinal manipulation, Low dose spinal manipulation, Moderate dose spinal manipulation | Intervention Type: OTHER; Name: Light Massage; Assigned to Arm(s): High dose massage, Low dose spinal manipulation, Moderate dose spinal manipulation
B: Arm Label: Exercise and connective tissue massage; Type: EXPERIMENTAL; Interventions: Behavioral: "Exercise" and "connective tissue massage" | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: "Exercise" | Intervention Type: BEHAVIORAL; Name: "Exercise" and "connective tissue massage"; Assigned to Arm(s): Exercise and connective tissue massage | Intervention Type: BEHAVIORAL; Name: "Exercise"; Assigned to Arm(s): Exercise
C: Arm Label: Craniosacral Therapy (CST); Type: EXPERIMENTAL; Interventions: Procedure: Craniosacral Therapy | Arm Label: Sham Craniosacral Therapy (SHAM); Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Craniosacral Therapy | Intervention Type: PROCEDURE; Name: Craniosacral Therapy; Assigned to Arm(s): Craniosacral Therapy (CST) | Intervention Type: PROCEDURE; Name: Sham Craniosacral Therapy; Assigned to Arm(s): Sham Craniosacral Therapy (SHAM)
D: Arm Label: Dry Needling of trigger point; Type: EXPERIMENTAL; Interventions: Other: Dry needling | Arm Label: Strain-counterstraing technique; Type: EXPERIMENTAL; Interventions: Other: Strain-counterstrain technique | Arm Label: Placebo manual technique; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo manual technique | Intervention Type: OTHER; Name: Dry needling; Assigned to Arm(s): Dry Needling of trigger point | Intervention Type: OTHER; Name: Strain-counterstrain technique; Assigned to Arm(s): Strain-counterstraing technique | Intervention Type: OTHER; Name: Placebo manual technique; Assigned to Arm(s): Placebo manual technique

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multiple Dose, Randomized, Double-blind, Placebo Controlled, Parallel Clinical Trial to Assess the Effect of Aclidinium Bromide/Formoterol Fumarate Fixed-dose Combination on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The present study is planned to evaluate the effect of the aclidinium bromide/formoterol fumarate 400/12 μg FDC BID on the hyperinflation, exercise endurance and physical activity in patients with moderate to severe COPD. Additionally, the effect of the behavioural intervention on top of aclidinium bromide/formoterol fumarate 400/12 μg will be assessed both on the exercise endurance and the physical activity.


Options:
A: Arm Label: Aclidinium Bromide / Formoterol Fumarate; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide / Formoterol Fumarate | Arm Label: Salmeterol / Fluticasone propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol / Fluticasone | Intervention Type: DRUG; Name: Aclidinium Bromide / Formoterol Fumarate; Assigned to Arm(s): Aclidinium Bromide / Formoterol Fumarate | Intervention Type: DRUG; Name: Salmeterol / Fluticasone; Assigned to Arm(s): Salmeterol / Fluticasone propionate
B: Arm Label: Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium/Formoterol | Arm Label: Placebo to Aclidinium/Formoterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium/Formoterol; Assigned to Arm(s): Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo to Aclidinium/Formoterol
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aclidinium bromide | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol Fumarate | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 5
D: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strengthening Mental Health Care in Chronic Care Patients With Hypertension. A Cluster Randomised Control Trial
Brief Summary: A pragmatic cluster randomized controlled trial (RCT) in 20 public sector primary care clinics in the Dr Kenneth Kaunda district of the North West Province of South Africa to assess mental health and health outcomes for depressed adults receiving hypertensive treatment by measuring the real-world effectiveness of a facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression. The control condition is enhanced usual primary health care where non-physician clinicians have been equipped with the basic skills to identify stress and depression/anxiety but with limited access to doctors authorized to prescribe antidepressant medication, and with no specific psychosocial interventions.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PC101+Mental Health | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PC101+Mental Health | Intervention Type: BEHAVIORAL; Name: PC101+Mental Health; Assigned to Arm(s): Control, Intervention
B: Arm Label: Self Help Plus; Type: EXPERIMENTAL; Interventions: Behavioral: Self Help Plus | Arm Label: Enhanced Treatment As Usual; Type: OTHER; Interventions: Other: Enhanced Treatment As Usual | Intervention Type: BEHAVIORAL; Name: Self Help Plus; Assigned to Arm(s): Self Help Plus | Intervention Type: OTHER; Name: Enhanced Treatment As Usual; Assigned to Arm(s): Enhanced Treatment As Usual
C: Arm Label: HAPIFED; Type: EXPERIMENTAL; Interventions: Behavioral: HAPIFED | Arm Label: CBT-E; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT-E | Intervention Type: BEHAVIORAL; Name: HAPIFED; Assigned to Arm(s): HAPIFED | Intervention Type: BEHAVIORAL; Name: CBT-E; Assigned to Arm(s): CBT-E
D: Arm Label: Depression Care; Type: EXPERIMENTAL; Interventions: Combination Product: evidence-based depression treatment | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: COMBINATION_PRODUCT; Name: evidence-based depression treatment; Assigned to Arm(s): Depression Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Home Telerehabilitation Program for People With Proximal Humerus Fracture Treated Conservatively: a Randomized Clinical Trial.
Brief Summary: The main objective of the study is to compare the clinical effects of the innovative telerehabilitation approach (TELE group) compared to face-to-face visits to a clinic (CLINIC group) for patients treated for a proximal humerus fracture.


Options:
A: Arm Label: Conservative; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group | Arm Label: Philos locking plate; Type: ACTIVE_COMPARATOR; Interventions: Device: Philos | Arm Label: Epoca prosthesis; Type: ACTIVE_COMPARATOR; Interventions: Device: Epoca | Intervention Type: DEVICE; Name: Philos; Assigned to Arm(s): Philos locking plate | Intervention Type: DEVICE; Name: Epoca; Assigned to Arm(s): Epoca prosthesis | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Conservative
B: Arm Label: Conservative /Physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Surgery with LCP T plate; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical treatment with LCP | Intervention Type: PROCEDURE; Name: Surgical treatment with LCP; Assigned to Arm(s): Surgery with LCP T plate
C: Arm Label: Osteosynthesis; Type: EXPERIMENTAL; Interventions: Procedure: Osteosynthesis | Arm Label: Non-surgical; Type: EXPERIMENTAL; Interventions: Procedure: Non-surgical management | Arm Label: Hemiarthroplasty; Type: EXPERIMENTAL; Interventions: Procedure: Hemiarthroplasty | Intervention Type: PROCEDURE; Name: Non-surgical management; Assigned to Arm(s): Non-surgical | Intervention Type: PROCEDURE; Name: Osteosynthesis; Assigned to Arm(s): Osteosynthesis | Intervention Type: PROCEDURE; Name: Hemiarthroplasty; Assigned to Arm(s): Hemiarthroplasty
D: Arm Label: Telerehabilitation; Type: EXPERIMENTAL; Interventions: Other: Rehabilitation (Physiotherapy) | Arm Label: Face-to-face intervention in a clinic; Type: ACTIVE_COMPARATOR; Interventions: Other: Rehabilitation (Physiotherapy) | Intervention Type: OTHER; Name: Rehabilitation (Physiotherapy); Assigned to Arm(s): Face-to-face intervention in a clinic, Telerehabilitation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis
Brief Summary: International clinical trial to compare ponesimod and teriflunomide in relapsing multiple sclerosis


Options:
A: Arm Label: OMB 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab subcutaneous injection, Drug: Teriflunomide-matching placebo capsules | Arm Label: TER 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Teriflunomide capsule, Drug: Matching placebo of ofatumumab subcutaneous injections | Intervention Type: DRUG; Name: Ofatumumab subcutaneous injection; Assigned to Arm(s): OMB 20 mg | Intervention Type: DRUG; Name: Teriflunomide-matching placebo capsules; Assigned to Arm(s): OMB 20 mg | Intervention Type: DRUG; Name: Teriflunomide capsule; Assigned to Arm(s): TER 14 mg | Intervention Type: DRUG; Name: Matching placebo of ofatumumab subcutaneous injections; Assigned to Arm(s): TER 14 mg
B: Arm Label: Rebif® New Formulation (IFN-beta-1a, RNF); Type: EXPERIMENTAL; Interventions: Drug: Rebif® New Formulation (IFN-beta-1a, RNF) | Arm Label: Placebo/RNF; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Rebif® New Formulation (IFN-beta-1a, RNF) | Intervention Type: DRUG; Name: Rebif® New Formulation (IFN-beta-1a, RNF); Assigned to Arm(s): Rebif® New Formulation (IFN-beta-1a, RNF) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/RNF | Intervention Type: DRUG; Name: Rebif® New Formulation (IFN-beta-1a, RNF); Assigned to Arm(s): Placebo/RNF
C: Arm Label: Ponesimod; Type: EXPERIMENTAL; Interventions: Drug: ponesimod | Arm Label: Teriflunomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: teriflunomide | Intervention Type: DRUG; Name: ponesimod; Assigned to Arm(s): Ponesimod | Intervention Type: DRUG; Name: teriflunomide; Assigned to Arm(s): Teriflunomide
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Copaxone; Assigned to Arm(s): Arm 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate Plaque Psoriasis
Brief Summary: This study will evaluate the clinical efficacy, the patients quality of life, and safety of oral apremilast 30 mg twice daily (BID) compared to placebo, in adult patients with moderate plaque psoriasis during the 16 week Placebo controlled Phase and then upto 1 year in the Extension Phase of the trial.


Options:
A: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Etanercept + Acitretin | Arm Label: Group C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Etanercept + Acitretin; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Group C
B: Arm Label: Induction Single Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Induction Monthly Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Induction Early Loading Dose; Type: EXPERIMENTAL; Interventions: Drug: AIN457A | Arm Label: Placebo Dose; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): Induction Single Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Monthly Dose | Intervention Type: DRUG; Name: AIN457A; Assigned to Arm(s): Induction Early Loading Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Dose
C: Arm Label: Apremilast; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo, Drug: Placebo-Apremilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Placebo-Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Apremilast, Placebo | Intervention Type: DRUG; Name: Placebo-Apremilast; Assigned to Arm(s): Apremilast, Placebo
D: Arm Label: ABP 501; Type: EXPERIMENTAL; Interventions: Biological: ABP 501 | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab | Intervention Type: BIOLOGICAL; Name: ABP 501; Assigned to Arm(s): ABP 501

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate Plaque Psoriasis
Brief Summary: This study will evaluate the clinical efficacy, the patients quality of life, and safety of oral apremilast 30 mg twice daily (BID) compared to placebo, in adult patients with moderate plaque psoriasis during the 16 week Placebo controlled Phase and then upto 1 year in the Extension Phase of the trial.


Options:
A: Arm Label: Therapeutic drug monitoring; Type: EXPERIMENTAL; Interventions: Other: Therapeutic drug monitoring | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Therapeutic drug monitoring; Assigned to Arm(s): Therapeutic drug monitoring | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
B: Arm Label: Apremilast; Type: EXPERIMENTAL; Interventions: Drug: Apremilast, Drug: Placebo, Drug: Placebo-Apremilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Placebo-Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Apremilast, Placebo | Intervention Type: DRUG; Name: Placebo-Apremilast; Assigned to Arm(s): Apremilast, Placebo
C: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A
D: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab | Arm Label: Risankizumab 75 mg (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for risankizumab | Arm Label: Risankizumab 150 mg (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab 150 mg (Part A), Risankizumab 75 mg (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Risankizumab 75 mg (Part A)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children
Brief Summary: Chronic pulmonary disease (CLD) is the most common manifestation of HIV/AIDS among children, accounting for more than 50% of HIV-associated mortality. Recently, a novel form of CLD, affecting more than 30% of African HIV-infected older children was described by Ferrand et al in Zimbabwe, high-resolution CT scanning findings showed predominantly small airways disease consistent with constrictive obliterative bronchiolitis (OB). . Azithromycin has anti-inflammatory activity and treatment of CLD with this agent may lead to suppression of generalized immune activation.

This specific aims of this project are to:

1. Primary objective: To investigate whether adjuvant treatment with azithromycin results in improvement in lung function in HIV-infected children with chronic lung disease, who are stable on antiretroviral therapy.
2. Secondary objectives:

   1. To investigate the intervention effect on mortality, exacerbations of lung disease, quality of life, morbidity.
   2. To investigate adverse events related to azithromycin treatment

In total, 400 children aged 6-16 years, living with HIV and diagnosed with CLD will be enrolled at Harare Children´s Hospital in Harare (Zimbabwe) and Queen Elizabeth Central Hospital in Blantyre (Malawi). These will receive weekly treatment with azithromycin or placebo during 12 months. Another 100 children (50 per site) living with HIV but with no CLD will be enrolled as a comparison group for laboratory sub-studies.

Lung function will be assess using spirometry and the Forced expiratory volume in the first minute (FEV1) will be the primary outcome. The mean change in FEV1 z-score levels will be compared between trial arms after 12 months of initiation of azithromycin treatment.


Options:
A: Arm Label: Azithomycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithomycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Azithromycin and Placebo | Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin and Placebo | Intervention Type: DRUG; Name: Azithromycin and Placebo; Assigned to Arm(s): Azithromycin, Placebo
C: Intervention Type: DRUG; Name: Intravenous Clarithromycin; Assigned to Arm(s): N/A
D: Arm Label: azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: A